Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT01325441
- Locations
- 🇺🇸
Texas Oncology- Fort Worth, Fort Worth, Texas, United States
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇺🇸Virginia Cancer Specialists, P.C., Fairfax, Virginia, United States
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01287364
- Locations
- 🇺🇸
Princeton Center for Clinical Research, Skillman, New Jersey, United States
🇺🇸Clinical Research Institute, Minneappolis, Minnesota, United States
🇺🇸Sylvania Research Associates, San Antonio, Texas, United States
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT01284517
- Locations
- 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸Clinical Innovations inc., Santa Ana, California, United States
🇺🇸Collaborative Neuroscience Network, Torrance, California, United States
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01143090
- Locations
- 🇺🇸
Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸FutureSearch Trials of Dallas, Dallas, Texas, United States
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 244
- Registration Number
- NCT01143077
- Locations
- 🇺🇸
Collaborative Neuroscience Network, South Bay, Torrance, California, United States
🇺🇸Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States
🇺🇸CRI Worldwide - Kirkbride Center, Philadelphia, Pennsylvania, United States
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
- Conditions
- Interventions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT01091662
- Locations
- 🇺🇸
West Los Angeles VA Medical Center, Los Angeles, California, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸The Sandra and Malcom Berman Brain & Spine Institute, Baltimore, Maryland, United States
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01082276
- Locations
- 🇺🇸
PAREXEL Clinical Pharmacology Research Unit, Baltimore, Maryland, United States
Midazolam Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01082263
- Locations
- 🇺🇸
CCT/Parexel, Culver City, California, United States
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01082250
- Locations
- 🇺🇸
California Clinical Trials (CCT), Glendale, California, United States
Digoxin Drug-Drug Interaction With Lurasidone HCl
- Conditions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01082289
- Locations
- 🇺🇸
California Clinical Trials, Culver City, California, United States